source
- Superluminal Medicines raises $60M Series B to launch Phase 1 trial of genetic obesity therapySuperluminal Medicines, a Boston‑based biotech, announced it has closed a $60 million Series B financing round. The capital will fund the company’s first‑in‑human study of its genetic obesity candi…
- Biopharma seeks data scientists as U.S. job market projected to grow 35%Biopharma companies are ramping up hiring for data scientists as the U.S. Bureau of Labor Statistics forecasts a 35% increase in data science jobs over the next decade. The surge reflects the growi…